Development of 1,2,3-triazole hybrids as multi-faced anticancer agents co-targeting EGFR/mTOR pathway and tubulin depolymerization
- 11 January 2025
- journal article
- Published by Elsevier in Bioorganic Chemistry
- Vol. 156, 108153
Abstract
No abstract availableKeywords
This publication has 96 references indexed in Scilit:
- Cancer-Associated Programmed Cell Death Mechanisms: Extended with Biochemical Markers and Experimental Approaches2024
- Interplay Between Autophagy and Apoptosis in Cancer: Mechanisms and Therapeutic Implications2024
- Design and Synthesis of Oxazole‐Linked Pyrazole Chalcone Derivatives: In‐Vitro Anticancer Evaluation and In‐Silico Molecular Docking StudiesChemistrySelect, 2023
- Anti–Epidermal Growth Factor Receptor Maintenance Therapy in Metastatic Colorectal Cancer—Another Piece to the PuzzleJAMA Network Open, 2023
- Cycloaddition Reactions of EnaminesEuropean Journal of Organic Chemistry, 2023
- 1,2,3-triazenes and 1,2,3-triazoles as antileishmanial, antitrypanosomal, and antiplasmodial agentsMedicinal Chemistry Research, 2022
- Synthesis, antimicrobial, and antioxidant activities of disubstituted 1,2,3-triazoles with amide-hydroxyl functionalityMedicinal Chemistry Research, 2022
- In Silico Approach in Drug Design and Drug Discovery: An Update2021
- Chalcone hybrids and their antimalarial activityArchiv der Pharmazie, 2020
- Synthesis of new 1,2,3‐triazolo[1,2‐a]benzotriazole derivatives or substituted 2,3‐benzo‐1,3a,6,6a‐tetraazapentalenes. IIJournal of Heterocyclic Chemistry, 1997